Positive PhIII data for Jazz sleep disorder drug
JZP-258 achieved primary and key secondary endpoints showing significant differences in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo
Read More
Tag: narcolespy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
